Hifectin was employed to deliver VEGF-C-targeted siRNA (siV2) and assess potency of the delivered siRNA against the breast tumors developed by subcutaneous administration of 5 × 104 of 4T1 cells (mouse breast cancer cells) in the right-front dorsum of a Balb/C female mouse (4 weeks old) of 18–20 gm each. The gene discussed is VEGFC; the disease is breast cancer.